Knight therapeutics announces regulatory submission of crexont® (carbidopa and levodopa) extended-release capsules in mexico

Montreal, aug. 05, 2025 (globe newswire) -- knight therapeutics inc., (tsx: gud) ("knight") a pan-american (ex-usa) specialty pharmaceutical company, announced today that its mexican affiliate, grupo biotoscana de especialidad s.a. de c.v., has submitted a marketing authorization application for crexont® to cofepris, the mexican health regulatory agency, for the treatment of parkinson's disease (pd), post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
AMRX Ratings Summary
AMRX Quant Ranking